or Try an Advanced Search...

    Fibroids Stocks List

    Symbol Grade Name % Change
    HOLX D Hologic, Inc. -0.19
    NBIX C Neurocrine Biosciences, Inc. 1.74
    PROF D Profound Medical Corp. 6.33
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Medical Instruments & Supplies
    Related Stock Lists: Bone Clinical Medicine Medicine Pain Uterine Fibroid Ablation Acid Alcohol Biopsy Birth Control Bone Disease Brachytherapy Breast Cancer Breast Imaging Breast Surgery Cancer Screening Cardiovascular Disease Clinical Development Contraception Diabetes

    Related ETFs - A few ETFs which own one or more of the above listed Fibroids stocks.

    Symbol Grade Name Weight
    PBE B PowerShares Dynamic Biotech & Genome 5.25
    IBRN D iShares Neuroscience and Healthcare ETF 4.94
    MNTL D Tema Neuroscience and Mental Health ETF 4.58
    EKG D First Trust Nasdaq Lux Digital Health Solutions ETF 4.11
    QQQN D VictoryShares Nasdaq Next 50 ETF 3.62
    View all Fibroids ETFs...
    Compare ETFs
    Compare EKG to QQQN Compare IBRN to MNTL Compare PBE to EKG

        Fibroids Stocks Recent News

        Date Stock Title
        May 14 PROF Profound Medical gets FDA okay for TULSA AI module
        May 14 NBIX Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
        May 14 PROF Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
        May 13 HOLX Hologic (HOLX) Is Considered a Good Investment by Brokers: Is That True?
        May 13 HOLX Hologic: Women's Health Play Looks Healthier Itself
        May 11 PROF Profound Medical Corp. (PROF) Q1 2024 Earnings Call Transcript
        May 11 PROF Profound Medical First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        May 9 PROF Profound Medical GAAP EPS of $0.26 beats by $0.57, revenue of $1.91M misses by $0.59M
        May 9 PROF Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
        May 9 NBIX How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
        May 9 NBIX Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
        May 9 NBIX Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
        Related Industries: Biotechnology Diagnostics & Research Medical Instruments & Supplies
        Related Stock Lists: Bone Clinical Medicine Medicine Pain Uterine Fibroid Ablation Acid Alcohol Biopsy Birth Control Bone Disease Brachytherapy Breast Cancer Breast Imaging Breast Surgery Cancer Screening Cardiovascular Disease Clinical Development Contraception Diabetes
        Fibroids

        Browse All Tags